[Skip to Content]
[Skip to Content Landing]
Views 273
Citations 0
Comment & Response
September 8, 2020

Chikungunya Virus–Like Particle Vaccine—Reply

Author Affiliations
  • 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
JAMA. 2020;324(10):1008-1009. doi:10.1001/jama.2020.11859

In Reply We described the results of a phase 2 clinical trial demonstrating the safety, tolerability, and durable immunogenicity of a CHIKV VLP vaccine at 6 chikungunya-endemic sites in the Caribbean.1 Dr Jaiswal and colleagues highlight the favorable safety profile of the vaccine and inquire as to the reason for the study participant withdrawals described as “investigator or study decision” and requested the genotype-specific neutralization assay results.